Are you talking about limitation in autologous CAR T whereas Azer-Cel is allogeneic?? That's why the allogeneic CAR T technology is being developed by many companies right now.
- Forums
- ASX - By Stock
- IMU
- Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial
IMU
imugene limited
Add to My Watchlist
7.14%
!
1.3¢

Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial, page-219
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M |
Open | High | Low | Value | Volume |
1.4¢ | 1.4¢ | 1.3¢ | $144.0K | 10.41M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
78 | 19040070 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 6091128 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
78 | 19078796 | 0.013 |
66 | 14045547 | 0.012 |
19 | 4930116 | 0.011 |
37 | 9292022 | 0.010 |
5 | 961155 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 6062487 | 14 |
0.015 | 10817566 | 46 |
0.016 | 10136745 | 37 |
0.017 | 8708633 | 19 |
0.018 | 5121090 | 23 |
Last trade - 12.22pm 18/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online